Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ivermectin 3 mg vs Stromectol 3 mg in Healthy Subjects
NCT05082753Phase 1Completed
- Sponsor
- Humanis
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CHILD-IVITAB in strongyloidiasis and onchocerciasis (2 arms), sponsored by Humanis. Primary endpoints: Maximum observed plasma concentration at 72 hours and Area under the concentration-time curve from time zero to 72 hours. Started Nov 2020; status: completed.
02
Drugs
CHILD-IVITAB
03
Conditions
strongyloidiasisonchocerciasis
Beyond the preview
Go deeper on NCT05082753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082753.